Bumetanide is a selective antagonist of Na-K-Cl cotransporter (NKCC1) which can reduce intracellular chloride concentrations and enhances the inhibitory effect of GABAergic neurons, an FDA-approved drug with the potential to treat or prevent cognitive impairment in SCZ syndrome (Lemonnier et al., 2016). This evidence concerns the gene SLC12A2 and Cognitive impairment.